SERum-bank for PANcreatic Cancer

Study Overview
=================
Brief Summary
-----------------
This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (<2cm), the chances of recovery are very good. But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. Today, there is no any effective means of detection... Blood markers can be a simple means of early detection

Detailed Description
-----------------
The purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.

Official Title
-----------------
SERum-bank for PANcreatic Cancer

Conditions
-----------------
Adenocarcinoma

Intervention / Treatment
-----------------
* Biological: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
ADENOCARCINOMA GROUP Inclusion Criteria: Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis. At the start of treatment (before surgery / 1st course of chemotherapy) Age ≥ 18 years Patient affiliated or entitled to a social security system Exclusion Criteria: Patient refusal Acute renal failure Child-Pugh B or C cirrhosis Patient under guardianship or curators Other synchronous cancer or history of cancer <5 years Language barrier CONTROL GROUP Inclusion Criteria: Age ≥ 40 years Patient affiliated or entitled to a social security system Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease Exclusion Criteria: Patient refusal Acute renal failure Child-Pugh B or C cirrhosis Patient under guardianship or curators Other synchronous cancer or history of cancer <5 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adenocarcinoma group<br>Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after. | Biological: Blood sample<br>* Blood sample will be performed<br>|
| Control group<br>Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit. | Biological: Blood sample<br>* Blood sample will be performed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum adiponectin concentration | Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%. | Months : 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum CA19.9 concentration | Measure by blood sample result Threshold for Comparison of diagnostic performance compared to serum adiponectin concentration | Months : 0, 3, 6, 9, 12 | 
| Tumor response and progression rates according to RECIST v1.1 | Tumor response and progression rates defined according to RECIST v1.1 criteria according to a serum threshold of the prognostic biomarker to be identified by logistic regression analyzes. | Month 12 | 
| Progression-free survival |  | Months : 24 | 
| Overall survival |  | Months : 24 | 
| Serum adiponectin concentration | Measure by blood sample result Serum adiponectin concentration to correlate with cancer progression or not. | Months : 3, 6, 9, 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adiponectin, Adenocarcinoma, Pancreatic cancer, Blood sample